Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

NCT00003109 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: irinotecan hydrochloride
DRUG: raltitrexed

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]